PACRA Maintains Entity Ratings of Martin Dow Marker Limited

Martin Dow Marker Limited (MDM or "the Company"), formerly known as Merck (Pvt.) Ltd., is a well-established and commercially prominent player in Pakistan's pharmaceutical sector. The business is led by the Akhai family, whose presence in the industry stretches back to 1960, bringing with it decades of sector expertise and strategic continuity. MDM is principally engaged in the manufacturing and marketing of pharmaceutical products, supported by a diversified portfolio of over 70 brands spanning key therapeutic areas including diabetes, cardiology, vitamins, analgesics, and antibiotics. The Company's five flagship brands, Evion, Sangobion, Concor, Neurobion, and Glucophage, each generate in excess of PKR 1 billion in annual sales, reflecting strong and enduring market acceptance. MDM operates under the Martin Dow Group, comprising four companies and housing prominent brands such as Lexotanil, Rocephin, and Glucophage, among others. Built on a foundation of strategic acquisitions and financial strength. Pakistan's pharmaceutical sector continues to exhibit strong resilience and broad-based structural expansion. Industry growth reached 15.2% on a Moving Annual Total (MAT) basis, with the market attaining a total valuation of PKR 1.2 trillion by January 2026. This growth trajectory is underpinned by a five-year MAT CAGR of 17.2%, driven by a large and growing population base, rising prevalence of chronic and infectious diseases, and progressively improving healthcare access. Sector profitability has recovered meaningfully, supported by greater pricing flexibility, easing input cost pressures, and improved operating leverage. Nevertheless, key risks persist, including high dependence on imported APIs, exposure to PKR volatility, regulatory constraints on essential medicines, and ongoing global supply chain disruptions. MDM has developed a comprehensive product portfolio across both chronic and acute therapeutic segments. The Group upholds stringent quality standards and global best practices, further reinforced by enduring alliances with multinational partners including Roche, Merck, Sanofi, and Boehringer Ingelheim. During CY25, MDM delivered topline growth of ~13%, with revenues reaching PKR 31.9 billion. Profitability improved alongside, underpinned by enhanced operational efficiencies that translated into improved gross and net profit margins. The Company maintains an adequate corporate governance framework, though meaningful opportunities exist for further strengthening, particularly in board composition and the formation of dedicated committees. The management team comprises seasoned professionals, supported by robust internal controls and well-established compliance systems. Looking ahead, MDM is focused on introducing new products aligned with evolving healthcare demands while actively working to broaden its export footprint. The financial risk profile of MDM is assessed as adequate, characterized by comfortable debt service coverages, sound cash flows, and a moderately stretched working capital cycle. The capital structure remains leveraged, with borrowings comprising a measured mix of long-term facilities deployed for capital expenditure and short-term lines utilized to support working capital requirements.
The ratings are dependent on the sustainability of improvements in the profitability matrix and market share while retaining sufficient cash flows and coverages. However, it is essential for the Company to maintain adequate debt metrics and remain aligned with the shared financial projections. Improvement in governance structure remains important for the ratings.

About the Entity
Martin Dow Marker Ltd is a subsidiary of Martin Dow Limited. Martin Dow Limited holds 75% shareholding while Marker Family holds the remaining 25%. Martin Dow Limited is owned by the Akhai Family, mainly Ali Akhai, son of late Mr. Jawed Akhai (the founding chairman of Martin Dow Group). Mr. Ali Akhai is the chairman of the Board of Directors. MDM has a three-member board including the Chairman, Mr. Javed Ghulam Muhammad, the company's CEO, and Mr. Syed Dawood, the independent Director.